A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...

Back pain is among the most common forms of pain patients endure, and can severely alter their quality of life and ability to ...

explained Seminowicz. Additional findings from complementary studies indicate individuals with low levels of CME during the acute stages of low back pain were more likely to develop chronic pain ...

Researchers assessed physiologic changes of the spine as well as the frequency of low back pain among astronauts during and after spaceflight.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) ...

A study reveals brain biomarkers PAF and CME can predict pain sensitivity and chronic pain risk with 88% accuracy. The ...